New aTyr Class Action Extends Investor Window to Nov. 2024–Sept. 2025 Ahead of Dec. 8 Deadline
The litigation stems from the EFZO‑FIT trial’s failure and an 83% one‑day stock drop.
Overview
- Hagens Berman announced the King v. aTyr complaint in the Southern District of California covering purchases from November 7, 2024 through September 12, 2025.
- The Law Offices of Frank R. Cruz urged investors to seek lead‑plaintiff status by December 8, 2025.
- Bronstein, Gewirtz & Grossman is soliciting claimants under a narrower alleged class period of January 16, 2025 to September 12, 2025.
- Plaintiffs allege aTyr and certain executives misled investors about efzofitimod’s efficacy and the EFZO‑FIT trial design, particularly claims about complete steroid tapering.
- aTyr disclosed on September 15 that EFZO‑FIT missed its primary endpoint, after which shares fell 83% to close at $1.02, and the company said it would consult the FDA on next steps.